日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Predicting checkpoint inhibitor-associated autoimmune diabetes: prospects and limitations

预测免疫检查点抑制剂相关自身免疫性糖尿病:前景与局限性

Herold, Kevan C; Perdigoto, Ana Luisa

Anti-CD3 mAb treatment reshapes infiltrating T and β cells in the islets in autoimmune diabetes.

抗 CD3 mAb 治疗可重塑自身免疫性糖尿病胰岛中浸润的 T 细胞和 β 细胞。

Wu Ying, Spurrell Maxwell, Lledó-Delgado Ana, Deng Songyan, Wang Dejiang, Liu Yang, Barkestani Mahsa Nouri, Perdigoto Ana Luisa, Herold Kevan C

CTLA-4 blockade shifts the B cell repertoire toward autoimmunity

CTLA-4阻断使B细胞库向自身免疫方向转变

Çakan, Elif; Wang, Meng; Dai, Yile; Mirouse, Adrien; Villanueva-Pachas, Clarence Rachel; Bouis, Delphine; Boeckers, Joshua M; Gera, Ruchi; Yraita, Sally; Clapp, Leslie; Perdigoto, Ana Luisa; Delmotte, Fabien R; Massad, Christopher; Bacchiocchi, Antonietta; Ring, Aaron M; Kluger, Yuval; Kluger, Harriet M; Herold, Kevan C; Meffre, Eric

Consensus-based disease definitions for endocrine immune-related adverse events of immune checkpoint inhibitors

基于共识的免疫检查点抑制剂内分泌免疫相关不良事件疾病定义

Zhu, Ling; Cheung, Yee-Ming M; Chiang, Cherie; Gallagher, Emily J; Hamnvik, Ole-Petter R; Mammen, Jennifer; Quandt, Zoe; Jones, Renisha; McDunn, Jon; Al-Bahadili, Huda; Angell, Trevor; Bancos, Irina; Betof Warner, Allison; Blackwell, Susan; Calabrese, Cassandra; Cho, Tracey A; Dougan, Michael; Ferreira, Michelle; Funchain, Pauline; Herndon, Justine; Johnson, Douglas B; Kennedy, Randol; Kheterpal, Meenal; Khouri, Michel; Lechner, Melissa G; Lim, Annette M; Markova, Alina; Meara, Alexa; Overton, Laura; Perdigoto, Ana Luisa; Sachithanandan, Nirupa; Sharon, Elad; Spain, Lavinia; Tsai, Katy; Yarchoan, Mark; Reynolds, Kerry L; Shariff, Afreen

Autoimmune origin for immune checkpoint inhibitor-diabetes revealed by deep immune phenotyping of the pancreas

通过对胰腺进行深入的免疫表型分析,揭示了免疫检查点抑制剂相关糖尿病的自身免疫起源

Quandt, Zoe; Young, Arabella; Barlow, Graham Larson; Smith, Jennifer A; Kusmartseva, Irina; Dong, Shen; Shapiro, Melanie R; Kang, Jee Hye; Felton, Jamie L; Nguyen, Vinh Q; Szot, Greg; Hassoun, Assad A; Perdigoto, Ana Luisa; Herold, Kevan C; Nolan, Garry; Bollyky, Paul L; Brusko, Todd M; Nakayama, Maki; Cooper, Stewart; Anderson, Mark S

Factors that increase class I MHC expression may contribute to the development of immune checkpoint inhibitor-induced diabetes

增加I类MHC表达的因素可能促进免疫检查点抑制剂诱发糖尿病的发生。

Aizenbud, Lilach; Savion Gaiger, Noam; Perdigoto, Ana Luisa; Mann, Jacqueline E; Torres, Madeline Candelas; Boland, Genevieve M; Lawless, Aleigha R; Silverman, Shahar; Schoenfeld, David Aaron; Destina, Jodhel I; Hasson, Nitzan; Tran, Thuy; Hurwitz, Michael; Austin, Matthew R; Sullivan, Ryan J; Herold, Kevan C; Kluger, Harriet M

Towards insulin independence in type 1 diabetes: Prospects for prevention and cure

迈向1型糖尿病胰岛素非依赖化:预防和治疗的前景

Sydney, Guy I; Perdigoto, Ana Luisa; Herold, Kevan C

Immune checkpoint inhibitor-induced diabetes can potentially be effectively treated with infliximab: a case report of two patients

免疫检查点抑制剂诱发的糖尿病可能可用英夫利昔单抗有效治疗:两例患者的病例报告

Savion Gaiger, Noam; Hurwitz, Michael E; Hafez, Navid; Kluger, Harriet M; Herold, Kevan C; Perdigoto, Ana Luisa

Germline genetic variants are associated with development of insulin-dependent diabetes in cancer patients treated with immune checkpoint inhibitors

生殖系遗传变异与接受免疫检查点抑制剂治疗的癌症患者发生胰岛素依赖型糖尿病有关。

Caulfield, Jasmine I; Aizenbud, Lilach; Perdigoto, Ana Luisa; Meffre, Eric; Jilaveanu, Lucia; Michalek, Dominika A; Rich, Stephen S; Aizenbud, Yariv; Adeniran, Adebowale; Herold, Kevan C; Austin, Matthew R; Kluger, Harriet

Response to "NLRC5 germline variants and their potential role in eliciting an immune response in patients with cancer treated with immune checkpoint inhibitors" by Xiang-Yu Meng

对孟祥宇所著“NLRC5种系变异及其在接受免疫检查点抑制剂治疗的癌症患者中诱导免疫反应的潜在作用”一文的回应

Aizenbud, Lilach; Schoenfeld, David A; Caulfield, Jasmine I; Mann, Jacqueline E; Austin, Matthew R; Perdigoto, Ana Luisa; Herold, Kevan C; Kluger, Harriet M